
12/09/2024
We have initiated testing on samples collected in Colombia from patients showing symptoms of Zika, Dengue, and Chikungunya. All patients provided consent prior to the collection of matched plasma and serum samples. This proactive surveillance approach enables our pharmaceutical partners to stay ahead of evolving infectious disease biomarkers, enhancing their response to these rapidly changing health threats.